NDA 012342 · Advanz Pharma
Parnate
Tranylcypromine Sulfate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 4, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1961
Feb 21, 1961
Approved uses
3
Original approval plus efficacy supplements
Registered trials
32
3 Phase 3, 1 recruiting
FAERS reports
804
501 serious, 40 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING:SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . Tranylcypromine sulfate tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)]. Hypertensive Crisis with Significant Tyramine Use Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine sulfate tablets or after tranylcypromine sulfate tablets discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals...
What it is approved for
From the label in effect Jul 25, 2025.
Tranylcypromine sulfate tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4), Warnings and Precautions (5) , and Drug Interactions (7)]. Tranylcypromine sulfate tablets are a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants ( 1 ) Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions ( 1 , 4 , 5 , 7 )
Mechanism: The mechanism of action of tranylcypromine sulfate tablets as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 1984 Supplement 28 · Efficacy
- Mar 22, 1984 Supplement 31 · Efficacy
- Feb 21, 1961 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDAMedication Guide
1 products under this application
- PARNATE · TRANYLCYPROMINE SULFATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tranylcypromine" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Tranexamic Acid for Upper Gastrointestinal BleedingPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT01713101 · 414 participants (planned) · Start Oct 2012 · Primary completion Jul 2015
Drug: Early intravenous tranexamic acid administration; placebo · For: Acute Upper Gastrointestinal Hemorrhage
Sites: Seongnam-si, South Korea
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Treatment of Orthostatic Hypotension in Autonomic FailurePivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223691 · 389 participants · Start Mar 2002 · Primary completion Jan 2017
Drug: Atomoxetine; Acarbose and 19 more · For: Autonomic Failure; Orthostatic Hypotension
Sites: Nashville, Tennessee
- The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as ThromboprophylaxisPivotal-lookingCompleted
Chang Gung Memorial HospitalAcademic, hospital or other
NCT02458729 · 294 participants · Start Aug 2012 · Primary completion Jul 2014
Drug: Tranexamic Acid 5%,5ml/amp (intraoperative); Tranexamic Acid 5%,5ml/amp (3 hours after operation) and 3 more · For: Osteoarthritis, Knee
Sites: Koahsiung, Taiwan
- Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage TrialPivotal-lookingStatus unknown
Kwong Wah HospitalAcademic, hospital or other
NCT03044184 · 220 participants (planned) · Start Apr 1, 2017 · Primary completion Jun 30, 2020
Drug: Tranexamic Acid · For: Stroke Hemorrhagic; Intracerebral Haemorrhage
Sites: Hong Kong, Hong Kong
Ankara Etlik City HospitalGovernment (non-federal)
NCT06970483 · 192 participants · Start Dec 1, 2023 · Primary completion Dec 1, 2024
Drug: Tranexamic acid; Misoprostol 200mcg Tab · For: Postpartum Hemorrhage; Cesarean Section Complications; Delivery Complication
Sites: Ankara, Turkey (Türkiye)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective95
- depression91
- drug interaction80
- headache72
- contraindicated product administered68
- nausea63
- insomnia61
- hypertensive crisis60
- anxiety51
- dizziness50
- hypertension50
- suicidal ideation46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 45 |
| 2006 | 53 |
| 2007 | 50 |
| 2008 | 59 |
| 2009 | 38 |
| 2010 | 39 |
| 2011 | 51 |
| 2012 | 27 |
| 2013 | 13 |
| 2014 | 12 |
| 2015 | 38 |
| 2016 | 44 |
| 2017 | 25 |
| 2018 | 29 |
| 2019 | 55 |
| 2020 | 30 |
| 2021 | 15 |
| 2022 | 21 |
| 2023 | 30 |
| 2024 | 40 |
| 2025 | 28 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Parnate (Tranylcypromine Sulfate)
2024 spending
$476K
Beneficiaries
36
231 claims
Per beneficiary
$13,229
$9.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $667,545 |
| 2021 | $641,622 |
| 2022 | $606,886 |
| 2023 | $508,230 |
| 2024 | $476,241 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- [Not Available].
Kudling R, Hartmut Schoels W, Kuhn J · Fortschr Neurol Psychiatr 2018 · Case Reports, Systematic Review
- How treatable is refractory depression?
Stewart JW, Deliyannides DA, McGrath PJ · J Affect Disord 2014 · Clinical Trial, Research Support, Non-U.S. Gov't
- Electrocardiographic effects of tranylcypromine vs. amitriptyline.
White K, O'Leary J, Razani J, et al. · J Clin Psychiatry 1983 · Clinical Trial, Comparative Study
- Phenelzine treatment of melancholia.
McGrath PJ, Stewart JW, Harrison W, et al. · J Clin Psychiatry 1986 · Clinical Trial, Comparative Study
- MAOIs in the contemporary treatment of depression.
Thase ME, Trivedi MH, Rush AJ · Neuropsychopharmacology 1995 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.